Shaylen Foley

Ms. Shaylen Foley

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in Vaccine: X
Verified
Journal Article
Open access
IKIshu Kataria
Ishu Kataria
MSMariam Siddiqui
Mariam Siddiqui
KTKatherine Treiman
Katherine Treiman
SFShaylen Foley
Shaylen Foley
MAMeenu Anand
Meenu Anand
RSRengaswamy Sankaranarayanan
Rengaswamy Sankaranarayanan
India accounts for one-fifth of the global burden of cervical cancer cases and mortality. A safe and effective vaccine to prevent human papillomavirus (HPV) infections, the primary cause of cervical malignancies, is available in India but multiple barriers lead to its low uptake in the country. Physicians are a key stakeholder and communicator in the Indian health system and have the potential to increase HPV vaccine uptake. We undertook formative research to understand awareness, perceptions and choices of physicians when recommending the HPV vaccine to parents of adolescent girls. We conducted in-depth interviews with 32 physicians in two districts of West Bengal. Data collection was carried out between July and August 2019. The data was transcribed, coded, and analyzed using NVivo software using the thematic analysis technique. Our findings suggest that while physicians are generally aware about the burden of cervical cancer and its prevention by HPV vaccination, they face several barriers to recommending the HPV vaccine routinely and strongly. These include the lack of national-level guidance on the age eligibility and dosage, lack of practice-level opportunities such as well or non-sick visits and other routine adolescent vaccines, practice-level barriers like out-of-pocket cost and vaccine availability, and perceived parental hesitancy arising from reluctance to discuss cervical cancer, its prevention, and HPV vaccination. Physicians in our study exhibited hesitancy when recommending the HPV vaccine. They also faced logistical barriers. It is important that the barriers pertaining to when and how physicians recommend the vaccine be tackled through further education, policy change, and development and implementation of interventions that are evidenced-based.

2 January 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
SFShaylen Foley
Shaylen Foley
JNJennifer Nkonga
Jennifer Nkonga
MFMarcie Fisher-Borne
Marcie Fisher-Borne
Health plans can influence pediatric and primary care providers and patients to understand HPV vaccination coverage and increase HPV vaccination uptake. By initiating vaccination at age nine, health plans can lay the groundwork for on-time HPV cancer prevention by age 13. In 2022, the American Cancer Society engaged 28 health plans in a 12-month HPV vaccination learning collaborative in which plans set their own quality improvement targets, implemented multi-pronged interventions, and joined quarterly best-practice sharing calls. Twenty-five of the 28 plans reported including a focus on ages 9 to 10. Preliminary pre-intervention data illustrate that vaccination rates from participating plans follow national trends and reaffirm existing gaps for HPV vaccination. Health plan interventions to address HPV vaccination are consistent with best practices but could be maximized to target initiation at ages 9–10 by using provider and patient reminders, targeted provider education, and dose-specific provider pay for performance and patient incentive programs. Health plans should explore future capacity to analyze non-HEDIS required data, including HPV initiation and HPV vaccination data for adolescents below age 13.

20 July 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
SFShaylen Foley
Shaylen Foley
AFAshleigh Flowers
Ashleigh Flowers
THTralisa Hall
Tralisa Hall
MJMatthew Jansen
Matthew Jansen
MBMichelle Burcin
Michelle Burcin
Human papillomavirus (HPV) is known to cause six different types of cancer. HPV vaccination can prevent over 90% of these cancers. Community health workers (CHWs) have the potential to drive HPV vaccination demand through education and navigation by addressing vaccine hesitancy and dis/misinformation and by reaching non-English speaking, vulnerable, or rural populations. Despite their possible reach, there is limited research on HPV vaccination education programs for CHWs. In 2020–2021, the American Cancer Society (ACS) HPV Cancer Free Texas (HPVCFT) Project implemented the eight-session Mission: HPVCFT Vaccination ECHO–CHW Program ten times. This manuscript details the program’s implementation processes and outcomes. The program used the Project ECHO model and was offered in both English and Spanish. One hundred and forty-six Texan CHWs completed pre- and post-training surveys. The participants demonstrated significant HPV vaccination knowledge increases and desirable shifts in their foundational HPV vaccination beliefs, including the belief that the HPV vaccine is for cancer prevention. The participants also reported increased confidence in communicating about the HPV vaccine in the community. Improving knowledge, beliefs, and confidence in HPV vaccination is the first step in addressing concerns and increasing uptake. Future research and interventions are needed to better understand how CHWs can be more systematically linked to vaccination opportunities or provided with clearer paths for directing patients to providers that vaccinate.

16 October 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
SFShaylen Foley
Shaylen Foley
AFAshleigh Flowers
Ashleigh Flowers
JIJennifer Isher-Witt
Jennifer Isher-Witt
KCKatherine Crawford
Katherine Crawford
JNJennifer Nkonga
Jennifer Nkonga
AGAnne H. Gaglioti
Anne H. Gaglioti
The human papillomavirus (HPV) vaccine could prevent 37,000 HPV-related cancers annually in the U.S. yet uptake is suboptimal. Health plans cover 95% of children, implement quality improvement (QI) interventions, and report the Healthcare Effectiveness Data and Information Set (HEDIS®) Immunizations for Adolescents (IMA) measure. The American Cancer Society (ACS) convened payors in the ACS HPV Vaccination Learning Collaborative from 2022 to 2024 in three 12-month cohorts. Participants set QI targets, implemented interventions, and joined best-practice sharing calls. ACS provided a data reporting tool, resources, and one-on-one support. Plans submitted aggregated vaccination data. We used Wilcoxon Signed Rank test to assess average rates pre- and post-intervention. Ten participants consented to 60-minute semi-structured interviews that we transcribed and analyzed thematically. In 2022, we engaged 27 plans (35 service lines) from 19 states with 264,089 enrolled 13-year-olds. In 2023, participants represented 14 plans (16 service lines) from 11 states with 127,554 enrolled 13-year-olds. The 2024 collaborative included 26 plans (39 service lines) from 17 states with 249,927 enrolled 13-year-olds. We saw significant percentage point (pp) increases in 2023 for HPV completion (+3.0pp, p < .01), meningococcal (+3.3pp, p < .05), tetanus, diphtheria, & pertussis (Tdap) (+4.8pp, p < .01), and IMA (+3.0pp, p < .01) and in 2024 for HPV completion (+3.0pp, p < .001), Tdap (+1.7pp, p < .05), and IMA (+2.0pp, p < .001). Qualitative successes included intervention adaptations, age 9 initiation, data use, and collaboration. Barriers included project duration, turnover, and provider buy-in. We found the QI learning collaborative model acceptable to health plans and supported implementation of QI interventions to increase HPV vaccination.

25 July 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
AFAshleigh Flowers
Ashleigh Flowers
SFShaylen Foley
Shaylen Foley
SSSwati Saxena
Swati Saxena
SBSutapa Biswas
Sutapa Biswas
PGPriya Ganeshkumar
Priya Ganeshkumar
MAMeenu Anand
Meenu Anand
Background: India accounts for one-fifth of global cervical cancer deaths, yet Human Papillomavirus (HPV) vaccination coverage remains low despite the World Health Organization (WHO) recommendations to initiate vaccination at age 9. With the national HPV vaccination campaign in 2026 and its approval for integration into India’s Universal Immunization Programme (UIP), strengthening physician knowledge, beliefs, and confidence in recommending the vaccine is critical. Methods: In 2023, the American Cancer Society and Cancer Foundation of India catalyzed two national medical societies, the Federation of Obstetric and Gynaecological Societies of India and the Indian Academy of Pediatrics, to educate physicians on HPV vaccination using a train-the-trainer (ToT) model. A mixed-methods evaluation, using the RE-AIM Framework, included pre- and post-training surveys assessing changes in knowledge, beliefs, confidence, and intent, as well as monthly engagement surveys and project reports analyzed using descriptive and inferential statistics. A fidelity assessment evaluated consistency of training delivery. Twenty in-depth interviews explored physician reactions and implementation of learnings, analyzed using a rapid approach. Results: A total of 18,206 physicians were trained. The post-training respondent group demonstrated higher HPV vaccination knowledge scores and more favorable responses in confidence, beliefs, and intent than the pre-training respondent group. The fidelity assessment demonstrated consistent delivery overall, with some variability in role play facilitation. Interviews highlighted increased physician confidence, peer knowledge sharing, and community engagement following the training. Medical societies reported strong program adoption and plans for continued efforts. Conclusions: A ToT physician training cascaded through medical societies is a feasible strategy to prepare physicians to recommend the HPV vaccine and address parental concerns at scale.